TABLE 2.
Misreporting of sexual behavior by type of contraception reported at the last study visit among women with detectable PSA, Zimbabwe, 2006–2007. a,b
| Contraceptive method | Delay ≤8.9 monthsc (n=102) |
Consistent method usersd (n=173) |
Delay ≤8.9 months and consistent method users (n=93) |
|---|---|---|---|
| N % | N % | N % | |
| Any hormonal methode | 39 (45.9) | 67 (44.1) | 36 (45.6) |
| Oral contraceptives | 31 (46.3) | 51 (42.5) | 29 (45.3) |
| Injectables | 8 (44.4) | 16 (50.0) | 7 (46.7) |
| Other methods | 10 (58.8) | 13 (61.9) | 7 (50.0) |
| Overall | 49 (48.0) | 80 (46.2) | 43 (46.2) |
| Fisher’s exact test P-value | |||
| OC, injectable, or non-HC methods | 0.62 | 0.24 | 0.95 |
| HC vs. non-HC methods | 0.43 | 0.16 | 0.78 |
PSA: prostate-specific antigen
PSA concentrations greater than 1.0 ng/mL were considered as providing evidence of semen exposure within the past 2 days.
Analysis was restricted to the subset of women (n=195) who tested positive for PSA (>1 ng/mL) in vaginal eluate and who had contraceptive method data available at their last MIRA study visit.
Median delay between the last measurement of contraceptive method and the PSA study.
Reported the same contraceptive method at the penultimate visit in the MIRA study, typically 3 months prior to the last visit.
Oral contraceptives or injectable hormonal contraception.